摘要
目前含铂两药化疗是晚期非小细胞肺癌（NSCLC）患者的一线治疗方案。然而，标准一线化疗方案的疗效已达到了一个平台，晚期NSCLC患者在一线治疗获得了客观缓解或疾病稳定后的维持治疗是目前研究的热点。培美曲塞成为晚期肺癌患者一线治疗达到缓解或稳定后的新的治疗手段，其耐受性好，提高了总体生存时间和无疾病进展时间，并且对于非鳞癌患者疗效显著。厄洛替尼（商品名：特罗凯）与一线化疗序贯治疗能显著延长患者无进展生存期，有研究表明标准治疗后的晚期NSCLC患者，无论病理类型、种族、性别、年龄、吸烟状态，应用厄洛替尼维持治疗均可临床获益且耐受性好。含铂两药一线化疗后使用吉非替尼（商品名：易瑞沙）维持治疗，可以给腺癌患者带来显著的临床获益。
Presently platinum-based doublets chemotherapy is the first-line treatment for advanced non-small-cell lung cancer patient .However, the efficacy of standard first-line treatment has stagnated. Maintenance therapy for patients with advanced NSCLC who responded to initial therapy has become a focus. Summarization：first, Peru maintenance therapy is well tolerated and offers superior OS and PFS, making it a new treatment paradigm for patients with advanced NSCLC who responded to initial therapy, especially Peru has greater efficacy ifi patients with non-squamous. Secondly, first-line chemotherapy followed Erlotinib prolongs survival in patient with advanced NSCLC. It has proved that Erlotinib as maintenance therapy is an active and well tolerated treatment after standard therapy in nearly all the patients with advanced NSCLC. No matter what pathological type, race, sex, age and cigarette smoking or not, Gefitinib maintenance therapy offers superior OS and PFS for patients with adenocarcinoma, who has accepted platinum-based doublets chemotherapy.
出处
《肿瘤研究与临床》
CAS
2010年第1期16-18,共3页
Cancer Research and Clinic
关键词
癌
非小细胞肺
药物疗法
联合
Carcinoma, non-small-cell lung
Drug therapy, combination
